Extraction issues of paclitaxel in nanocrystals

Journal of Biomedical Nanotechnology

Volumn 6, Issue 2, 2010, Pages 198-201

  Deng, Jiexin ^a   Huang, Leaf ^a   Liu, Feng ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

Biodistribution; Hplc analysis; Hplc extraction; Nano Carrier system; Paclitaxel; Pharmacokinetics

Indexed keywords

BIODISTRIBUTIONS; DRUG CARRIER; EXPONENTIAL GROWTH; EXTRACTION EFFICIENCIES; EXTRACTION RECOVERY; HPLC ANALYSIS; HYDROPHOBIC DRUG; NANOCARRIERS; NANOMICELLES; PACLITAXEL;

DRUG PRODUCTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NANOCRYSTALS; PHARMACOKINETICS;

EXTRACTION;

NANOCARRIER; NANOCRYSTAL; PACLITAXEL; SOLID LIPID NANOPARTICLE; SOLVENT;

ANIMAL EXPERIMENT; ARTICLE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; LUNG; MOUSE; NONHUMAN; SPLEEN;

ANIMALS; CHEMICAL FRACTIONATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; LINEAR MODELS; MICE; NANOPARTICLES; NANOTECHNOLOGY; PACLITAXEL; SOLVENTS; TISSUE DISTRIBUTION;

EID: 77955451082     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2010.1104     Document Type: Article

References (20)

1. C. Lipinski, Poor aqueous solubility - An industry wide problem in drug discovery. Am. Pharm. Rev. 5, 82 (2002).
2. H. Lou, X. Zhang, L. Gao, F. Feng, J. Wang, X. Wei, Z. Yu, D. Zhang, and Q. Zhang, In vitro and in vivo antitumor activity of oridonin nanosuspension. Int. J. Pharm. 379, 181 (2009).
3. M. Weiner and I. L. Bernstein, Adverse Reactions to Drug Formulation Agents: A Handbook of Excipients, Dekker, New York (1989), pp. x, 463.
4. T. C. Yih and M. Al-Fandi, Engineered nanoparticles as precise drug delivery systems. J. Cell Biochem. 97, 1184 (2006).
5. P. M. Schlag and U. S. Stein (eds.), Regional cancer therapy, Cancer Drug Discovery and Development, Humana Press, Inc., Totowa, NJ (2007), pp. 163-179.
6. G. J. R. Charrois and T. M. Allen, Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim. Biophys. Acta Biomembr. 1663, 167 (2004).
7. D. B. Chen, T. Z. Yang, W. L. Lu, and Q. Zhang, In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem. Pharm. Bull. 49, 1444 (2001).
8. F. Liu, J. Y. Park, Y. Zhang, C. Conwell, S. R. Bathula, and L. Huang, Targeted cancer therapy with novel high drug-loading nanocrystals. J. Pharm. Sci. (2010), in press.
9. E. Merisko-Liversidge, G. G. Liversidge, and E. R. Cooper, Nano-sizing: A formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18, 113 (2003).
10. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzard, R. Margalit, and R. Langer, Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechol. 2, 751 (2007).
11. Y. Tan, J. P. Zhou, X. Y. Tong, and F. Feng, LC-MS/MS for determination of paclitaxel in rat tissues: Application to a biodistribution study of paclitaxel nanoliposome modified by PEO-PPO-PEO triblock copolymers. Anal. Lett. 39, 1349 (2006).
12. H. Yonemoto, S. Ogino, M. N. Nakashima, M. Wada, and K. Nakashima, Determination of paclitaxel in human and rat blood samples aftear administration of low dose paclitaxel by HPLC-UV detection. Biomed. Chromatogr. 21, 310 (2007).
13. J. G. Supko, R. V. Nair, M. V. Seiden, and H. Lu, Adaptation of solid phase extraction to an automated column switching method for online sample cleanup as the basis of a facile and sensitive high-performance liquid chromatography assay for paclitaxel in human plasma. J. Pharmaceut. Biomed. 21, 1025 (1999).
14. B. E. Rabinow, Nanosuspensions in drug delivery. Nat. Rev. Drug. Discov. 3, 785 (2004).
15. 14C]pyruvate through the portal vien. Int. J. Biochem. 15, 45 (1983).
16. D. Peavy, J. Taylor, and L. Jefferson, Correlation of albumin production rates and albumin mRNA levels in livers of normal, diabetic, and insulin-treated diabetic rats, Proc. Natl. Acad. Sci. 75, 5879 (1978).
17. J. Horton, J. Goldstein, and M. Brown, SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125 (2002).
18. R. Sokol, W. Balistreri, J. Hoofnagle, and E. Jones, Vitamin E deficiency in adults with chronic liver disease. Am. J. Clin. Nutr. 41, 66 (1985).
19. A. Kotronen and H. Yki-Jarvinen, Fatty liver a novel component of the metabolic syndrome. Arterioscler Thromb Vasc. Biol. 27, 2276 (2007).
20. B. Van Eerdenbrugh, G. Van den Mooter, and P. Augustijns, Topdown production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. Int. J. Pharm. 364, 64 (2008).